



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/743,750 01/16/2001		Ichiro Azuma	0020-4802P	7730
2292 75	90 10/02/2003	EXAMINE		INER
BIRCH STEW PO BOX 747	VART KOLASCH & BII	FORD, VANESSA L		
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1645 DATE MAILED: 10/02/2003	, 10

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application No.	Applicant(s)			
	065	A - 4! O	09/743,750	AZUMA ET AL.			
	Οπις	Action Summary	Examiner	Art Unit			
			Vanessa L. Ford	1645			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)⊠	Respons	ive to communication(s) filed on $16 J$	lanuary 2001 .				
2a) <u></u> ☐	This action is FINAL . 2b) This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 1-3,5-8,10,11 and 13-25 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s)_	is/are allowed.					
6) Claim(s) is/are rejected.							
7)	Claim(s) _	is/are objected to.					
•		1-3,5-8,10,11 and 13-25 are subject	to restriction and/or election req	uirement.			
· · · · <u> </u>	on Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ⊡ None of:							
		tified copies of the priority documents	s have been received.				
	2. Cer	tified copies of the priority documents	s have been received in Applicat	ion No			
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 							
Attachment	t(s)						
2) Notice 3) Inform	e of Draftsper mation Disclo	ce's Cited (PTO-892) rson's Patent Drawing Review (PTO-948) sure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)			
J.S. Patent and Tr	rademark Office						

Application/Control Number: 09/743,750

Art Unit: 1645

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Election/Restrictions

Group I Claims 1-3 and 5 are drawn to a lyophilized formulation obtainable by lyophilization of an oil-in-water emulsion comprising a bacterial component, an oil, an surfactant and a stabilizer as well as an amino acid or urea.

Group II Claims 6-8 and 10 are drawn to a method of making the lyophilized formulation.

Group III Claims 11 and 13-20 are drawn to a making the oil-in-water emulsion.

Group IV Claims 21-25 are drawn to an oil-in-water emulsion.

2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is a lyophilized formulation obtainable by lyophilization of an oil-in-water emulsion comprising a bacterial component, an oil, an surfactant and a stabilizer as well as an amino acid or urea. The technical feature lacks novelty under PCT Article 33(2) as being anticipated by Unger (*U.S. Patent No.*

Page 3

Application/Control Number: 09/743,750

Art Unit: 1645

6,416,740, published July 9, 2002) teaches therapeutic compositions comprising microspheres, an oil, a surfactant and a therapeutic compound (see the Abstract). Unger teaches that other components such as amino acids (i.e. glycine, serine, etc.) may be added to the invention (columns 15-16). Unger teaches that stabilizers may be added to the invention to enhance the surfactants (column 19-20). Unger teaches that the therapeutic component of the invention may include for example subunits of bacteria such as Myocobacteria or Corynebacteria (column 31-32). Unger teaches the formation of an oil-in-water emulsion using the components of the invention (column 87, Example 22). Although the term "lyophilized" is a process limitation, Unger teaches that freeze drying (lyophilization) is useful to remove water and organic materials from the composition see (column 57, lines 7-10 and Example, 11, column 83). Therefore, Unger teaches a stable lyophilized formulation. Group I is the main invention in this application and it lacks novelty, therefore the other claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. Inasmuch as the technical feature does not define a contribution over the art, it is not "special" within the meaning of PCT Rule 13.2 and therefore, Groups I-IV lack unity of invention.

Application/Control Number: 09/743,750

Art Unit: 1645

3. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308–0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (703) 308-4242.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (703) 308-4735. The examiner can normally be reached on Monday – Friday from 7:30 AM to 4:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (703) 308–3909.

Vanessa L. Ford Biotechnology Patent Examiner September 28, 2003

> LYNETTE R. F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600